According to a recent report released by MIC (Market Intelligence and Consulting Institute), US and European companies have higher R&D strengths in blood glucose technology deployment. Among top 30 patent assignees, 26 companies were from the United States, three from Europe and one from Japan.
Top 10 Assignees of Blood Glucose Meters
|
No.
|
US Patent No.
|
Title
|
Assignee
|
|
1
|
6,175,752
|
Analyte monitoring device and methods of use
|
Abbott
|
|
2
|
6,001,067
|
Device and method for determining analyte levels
|
Mark C. Shults
|
|
3
|
6,565,509
|
Analyte monitoring device and methods of use
|
E. Heller & Company.
|
|
4
|
6,741,877
|
Device and method for determining analyte levels
|
Markwell Medical Institute, Inc.
|
|
5
|
5,791,344
|
Patient monitoring system
|
Alfred E. Mann Foundation For Scientific Research
|
|
6
|
6,329,161
|
Subcutaneous glucose electrode
|
Abbott
|
|
7
|
5,586,553
|
Transcutaneous sensor insertion set
|
Medtronic, Inc.
|
|
8
|
6,560,471
|
Analyte monitoring device and methods of use
|
Abbott
|
|
9
|
6,248,067
|
Analyte sensor and holter-type monitor system and method of using the same
|
Medtronic, Inc.
|
|
10
|
6,484,046
|
Electrochemical analyte sensor
|
Abbott
|
Source: MIC, June 2015
The findings of blood glucose technology deployment analyses showed that US companies hold more non-invasive blood glucose meter patents than European peers. Three technology fields associated with non-invasive blood glucose meters were identified by text mining and the results showed that US companies own 89.6% of Optical Sensor patents, 91.3% Light Source patents, and 100% Light for Quantitative Analysis patents.?
"It is observed that US companies have been more active in R&D of non-invasive blood glucose meters than European peers using optical techniques to measure blood glucose concentration with the top-notch measurement technologies such as infrared light technology, near/far infrared light technology and inflorescent technology," says David Chen, senior industry analyst with MIC. "The objectives of those US companies are to control next generation key technologies related to blood glucose meters to tap into opportunities with smart connected devices that have microarchitecture, intelligence and cloud-based features. Blood glucose meters not only serve as an effective tool to help diabetes patients control blood glucose concentration but also as a wearable device for health management and diabetes prevention."
Based on the findings, the abovementioned medical devices companies have made an aggressive move in patent deployment. Latecomers in the blood glucose meter market are unable to avoid patent infringements and therefore are advised to sign patent licensing and technology transfer agreements for non-invasive optical sensing technologies to help them leap forward directly to next-generation blood glucose meter technologies, breaking free from traditional patent constraints.
To see more about this report, please visit: Blood Glucose Meter: Technology, Business Opportunity and Patent Analysis, Insight into Major Vendors' Patent Deployment
For future receipt of press releases, or more information about MIC research findings, please contact MIC Public Relations.
About MIC
Market Intelligence & Consulting Institute (MIC), based in Taipei, Taiwan, was founded in 1987. MIC is Taiwan's premier IT industry research and consulting firm providing intelligence, in-depth analysis, and strategic consulting services on global IT product and technology trends, focusing on markets and industries in Asia-Pacific. MIC is part of the Institute for Information Industry. https://mic.iii.org.tw/english